Alexander Sapir | executive |
Alan Musso | executive |
Matthew Biegler | analyst |
Iain Fraser | executive |
Joori Park | analyst |
Dae Gon Ha | analyst |
Good morning and welcome to Fulcrum Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live and can be accessed on the Investors section of Fulcrum's website at www.fulcrumtx.com and is being recorded.Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations, plans, clinical development time lines and financial projections.
While these forward-looking statements represent Fulcrum's view as of today, this should not be relied upon as representing the company's views in the future.Fulcrum may update these statements in the future, but is not taking on an obligation to do so.